Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is based in Miami, Florida.

Longeveron Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

LONGEVERON, SELECTED AS A STARTUP HEALTH ALZHEIMER'S DISEASE MOONSHOT COMPANY, WILL PARTICIPATE IN STARTUP HEALTH APOLLO HOUSE DURING JPM WEEK 2026.

LONGEVERON, SELECTED AS A STARTUP HEALTH ALZHEIMER'S DISEASE MOONSHOT COMPANY, WILL PARTICIPATE IN STARTUP HEALTH APOLLO HOUSE DURING JPM HEALTHCARE WEEK 2026

THE PATENT RELATES TO METHODS OF ADMINISTERING THERAPEUTICALLY EFFECTIVE AMOUNTS OF ISOLATED ALLOGENEIC MESENCHYMAL STEM CELLS (MSCS) TO PATIENTS WITH AGING-RELATED FRAILTY WITH INFLAMMAGING AND ALSO TO TREAT PATIENTS WITH NON-ISCHEMIC DILATED CARDIOMYOPATHY NON-ISCHEMIC DILATED CARDIOMYOPATHY IS A PROGRESSIVE DISORDER WITH NO CURRENT CURE, OFTEN LEADING TO HEART TRANSPLANTATION NO APPROVED TREATMENTS FOR AGING-RELATED FRAILTY, A SYNDROME AFFECTING OLDER INDIVIDUALS THAT IMPAIRS HUMAN HEALTHSPAN, AND IS CHARACTERIZED BY WEAKNESS, LOW PHYSICAL ACTIVITY, SLOWED MOTOR PERFORMANCE, EXHAUSTION, AND UNINTENTIONAL WEIGHT LOSS LAROMESTROCEL, A MESENCHYMAL STEM CELL THERAPY, HAS DELIVERED POSITIVE INITIAL RESULTS ACROSS TWO CLINICAL TRIALS IN AGING-RELATED FRAILTY MIAMI, DEC. 02, 2025 (GLOBE NEWSWIRE) -- LONGEVERON INC. (NASDAQ: LGVN), A CLINICAL STAGE BIOTECHNOLOGY COMPANY DEVELOPING CELLULAR THERAPY FOR LIFE-THREATENING, RARE PEDIATRIC AND CHRONIC AGING-RELATED CONDITIONS, TODAY ANNOUNCED THAT THE CANADIAN INTELLECTUAL PROPERTY OFFICE (CIPO) HAS GRANTED A PATENT COVERING ADMINISTRATION OF LAROMESTROCEL (LOMECEL-B), THE COMPANY'S PROPRIETARY MESENCHYMAL STEM CELLS (MSCS), FOR THE TREATMENT OF PATIENTS WITH SYMPTOMS OF AGING-RELATED FRAILTY AND ALSO FOR THE TREATMENT OF NON-ISCHEMIC DILATED CARDIOMYOPATHY (NIDCM). CANADIAN PATENT NO.

LONGEVERON GRANTED CANADIAN PATENT FOR METHOD OF USING STEM CELLS TO TREAT NON-ISCHEMIC DILATED CARDIOMYOPATHY AND AGING-RELATED FRAILTY IN PATIENTS WITH INFLAMMAGING

RESULTS OBTAINED IN THE PHASE 2 PLACEBO-CONTROLLED CLEAR-MIND CLINICAL TRIAL SHOWED THAT TREATMENT WITH STEM CELL THERAPY LAROMESTROCEL WAS ASSOCIATED WITH A REDUCTION IN MRI MEASURED NEUROINFLAMMATION COMPARED TO PLACEBO ACROSS MULTIPLE KEY BRAIN REGIONS, INCLUDING KEY ALZHEIMER'S DISEASE-ASSOCIATED REGIONS, MOST NOTABLY IN THE HIPPOCAMPUS REDUCTION IN HIPPOCAMPAL NEUROINFLAMMATION, MEASURED USING MRI ASSESSED FREE WATER, CORRELATED STRONGLY WITH PRESERVATION OF HIPPOCAMPAL VOLUME AND WITH CLINICAL OUTCOMES FINDINGS SUGGEST A SUSTAINED ANTI-INFLAMMATORY EFFECT OF LAROMESTROCEL, REINFORCING ITS PROPOSED MECHANISM OF ACTION IN THE TREATMENT OF MILD ALZHEIMER'S DISEASE MIAMI, DEC. 01, 2025 (GLOBE NEWSWIRE) -- LONGEVERON INC. (NASDAQ: LGVN), A CLINICAL STAGE BIOTECHNOLOGY COMPANY DEVELOPING CELLULAR THERAPY FOR LIFE-THREATENING, RARE PEDIATRIC AND CHRONIC AGING-RELATED CONDITIONS, TODAY ANNOUNCED THAT ITS SUBMISSION ENTITLED REDUCED BRAIN NEUROINFLAMMATION AFTER LAROMESTROCEL TREATMENT IN MILD AD: RESULTS FROM THE CLEAR MIND STUDY IS BEING PRESENTED IN A POSTER PRESENTATION AT THE 18TH CLINICAL TRIALS ON ALZHEIMER'S DISEASE CONFERENCE (CTAD 2025) BEING HELD DECEMBER 1-4, 2025 IN SAN DIEGO, CA. LAROMESTROCEL, A STEM CELL THERAPY THAT HAS MULTIPLE POTENTIAL MECHANISMS OF ACTION TO ADDRESS INFLAMMATORY RESPONSES IN THE BRAIN, OFFERS THE POTENTIAL TO ADDRESS THE UNDERLYING PATHOLOGY OF ALZHEIMER'S DISEASE, SAID JOSHUA HARE, M.D.

LONGEVERON NEW MRI BIOMARKER DATA LINKING NEUROINFLAMMATION TO CLINICAL OUTCOMES IN PATIENTS WITH MILD ALZHEIMER'S DISEASE PRESENTED AT THE CLINICAL TRIALS ON ALZHEIMER'S DISEASE CONFERENCE (CTAD 2025)

MIAMI, NOV. 19, 2025 (GLOBE NEWSWIRE) -- LONGEVERON INC. (NASDAQ: LGVN), A CLINICAL STAGE BIOTECHNOLOGY COMPANY DEVELOPING CELLULAR THERAPY FOR LIFE-THREATENING, RARE PEDIATRIC AND CHRONIC AGING-RELATED CONDITIONS, TODAY ANNOUNCED THAT ITS SUBMISSION ENTITLED REDUCED BRAIN NEUROINFLAMMATION AFTER LAROMESTROCEL TREATMENT IN MILD AD: RESULTS FROM THE CLEAR MIND STUDY HAS BEEN SELECTED FOR A POSTER PRESENTATION AT THE 18TH CLINICAL TRIALS ON ALZHEIMER'S DISEASE CONFERENCE (CTAD 2025) TO BE HELD DECEMBER 1-4, 2025 IN SAN DIEGO, CA. WE ARE EXCITED TO HAVE BEEN SELECTED TO PRESENT IMPORTANT LAROMESTROCEL DATA AT THIS LEADING FORUM FOR ALZHEIMER'S RESEARCH AND CLINICAL INVESTIGATION, SAID JOSHUA HARE, CO-FOUNDER, CHIEF SCIENCE OFFICER AND EXECUTIVE CHAIRMAN OF LONGEVERON.

LONGEVERON LAROMESTROCEL DATA IN ALZHEIMER'S DISEASE SELECTED FOR POSTER PRESENTATION AT THE CLINICAL TRIALS ON ALZHEIMER'S DISEASE CONFERENCE (CTAD 2025)

THE PATENT RELATES TO METHODS OF ADMINISTERING THERAPEUTICALLY EFFECTIVE AMOUNTS OF ISOLATED ALLOGENEIC MESENCHYMAL STEM CELLS (MSCS) TO PATIENTS WITH AGING-RELATED FRAILTY WITH INFLAMMAGING NO APPROVED TREATMENTS FOR AGING-RELATED FRAILTY, A SYNDROME AFFECTING OLDER INDIVIDUALS THAT IMPAIRS HUMAN HEALTHSPAN, AND IS CHARACTERIZED BY WEAKNESS, LOW PHYSICAL ACTIVITY, SLOWED MOTOR PERFORMANCE, EXHAUSTION, AND UNINTENTIONAL WEIGHT LOSS LAROMESTROCEL, A MESENCHYMAL STEM CELL THERAPY, HAS DELIVERED POSITIVE INITIAL RESULTS ACROSS TWO CLINICAL TRIALS IN AGING-RELATED FRAILTY MIAMI, NOV. 12, 2025 (GLOBE NEWSWIRE) -- LONGEVERON INC. (NASDAQ: LGVN), A CLINICAL STAGE BIOTECHNOLOGY COMPANY DEVELOPING CELLULAR THERAPY FOR LIFE-THREATENING, RARE PEDIATRIC AND CHRONIC AGING-RELATED CONDITIONS, TODAY ANNOUNCED THAT THE UNITED STATES PATENT AND TRADEMARK OFFICE (USPTO) HAS GRANTED A PATENT COVERING ADMINISTRATION OF THE COMPANY'S PROPRIETARY MESENCHYMAL STEM CELLS (MSCS) FOR THE TREATMENT OF PATIENTS WITH SYMPTOMS OF AGING-RELATED FRAILTY. U.S. PATENT NO.

LONGEVERON GRANTED U.S. PATENT FOR METHOD OF TREATING AGING-RELATED FRAILTY IN PATIENTS WITH INFLAMMAGING USING ITS PROPRIETARY STEM CELL THERAPY

LAROMESTROCEL IS A PROPRIETARY, SCALABLE, ALLOGENEIC CELLULAR THERAPY BEING EVALUATED TO IMPROVE THE CLINICAL OUTCOMES OF CHILDREN WITH HLHS FULL ENROLLMENT ACHIEVED FOR PIVOTAL PHASE 2B CLINICAL TRIAL (ELPIS II) EVALUATING LAROMESTROCEL AS A POTENTIAL ADJUNCT TREATMENT FOR HLHS, A RARE PEDIATRIC DISEASE AND ORPHAN-DESIGNATED INDICATION ELPIS II TOP-LINE TRIAL RESULTS ARE ANTICIPATED IN THE THIRD QUARTER OF 2026 MIAMI, OCT. 27, 2025 (GLOBE NEWSWIRE) -- LONGEVERON INC. (NASDAQ: LGVN), A CLINICAL STAGE BIOTECHNOLOGY COMPANY DEVELOPING CELLULAR THERAPIES FOR LIFE-THREATENING, RARE PEDIATRIC AND CHRONIC AGING-RELATED CONDITIONS, TODAY ANNOUNCED THAT JOSHUA M. HARE, MD, FACC, FAHA, LONGEVERON'S CO-FOUNDER, CHIEF SCIENCE OFFICER AND EXECUTIVE CHAIRMAN WAS INTERVIEWED ON NATIONAL PUBLIC RADIO'S (NPR) BIOTECH NATION WITH DR. MOIRA GUNN.

LONGEVERON CO-FOUNDER AND CHIEF SCIENCE OFFICER DR. JOSHUA HARE INTERVIEWED ON NPR'S BIOTECH NATION DISCUSSING POTENTIAL BREAKTHROUGH STEM CELL THERAPY FOR HYPOPLASTIC LEFT HEART SYNDROME (HLHS), A RARE PEDIATRIC CONGENITAL HEART DEFECT

MIAMI, OCT. 06, 2025 (GLOBE NEWSWIRE) -- LONGEVERON INC. (NASDAQ: LGVN), A CLINICAL STAGE BIOTECHNOLOGY COMPANY DEVELOPING CELLULAR THERAPIES FOR LIFE-THREATENING, RARE PEDIATRIC AND CHRONIC AGING-RELATED CONDITIONS, TODAY ANNOUNCED THAT IT WILL PARTICIPATE IN THE 4TH ANNUAL ROTH HEALTHCARE OPPORTUNITIES CONFERENCE. LONGEVERON MANAGEMENT WILL HOST ONE-ON-ONE MEETINGS WITH INVESTORS AT THE CONFERENCE TO BE HELD OCTOBER 9, 2025 IN NEW YORK.

LONGEVERON TO PARTICIPATE IN THE 4TH ANNUAL ROTH HEALTHCARE OPPORTUNITIES CONFERENCE

EXPLORING POTENTIAL PARTNERSHIPS AND STRATEGIC OPPORTUNITIES FOR THE COMPANY'S STEM CELL THERAPY PROGRAM IN ALZHEIMER'S DISEASE ALZHEIMER'S DISEASE DEVELOPMENT PROGRAM WITH POSITIVE DATA IN SUCCESSFUL PHASE 1 AND PHASE 2A CLINICAL TRIALS CLEAR REGULATORY PATHWAY FOLLOWING POSITIVE TYPE B MEETING WITH U.S. FDA FDA HAS GRANTED LAROMESTROCEL BOTH REGENERATIVE MEDICINE ADVANCED THERAPY (RMAT) DESIGNATION AND FAST TRACK DESIGNATION FOR THE TREATMENT OF MILD ALZHEIMER'S DISEASE MIAMI, SEPT. 22, 2025 (GLOBE NEWSWIRE) -- LONGEVERON INC. (NASDAQ: LGVN), A CLINICAL STAGE BIOTECHNOLOGY COMPANY DEVELOPING CELLULAR THERAPIES FOR LIFE-THREATENING, RARE PEDIATRIC AND CHRONIC AGING-RELATED CONDITIONS, TODAY ANNOUNCED THAT IT WILL PARTICIPATE IN THE ALLIANCE FOR REGENERATIVE MEDICINE'S CELL & GENE MEETING ON THE MESA TAKING PLACE OCTOBER 6-8, 2025 IN PHOENIX, ARIZONA.

LONGEVERON TO ATTEND ALLIANCE FOR REGENERATIVE MEDICINE'S CELL & GENE MEETING ON THE MESA

THAN POWELL, CHIEF BUSINESS OFFICER AND HEAD OF BUSINESS DEVELOPMENT, APPOINTED INTERIM CEO DR. JOSHUA HARE, CO-FOUNDER AND CHIEF SCIENCE OFFICER, APPOINTED EXECUTIVE CHAIRMAN OF THE BOARD OF DIRECTORS WA'EL HASHAD TO STEP DOWN AS CEO AND BOARD MEMBER NATIONAL SEARCH TO OCCUR FOR PERMANENT CEO MIAMI, SEPT. 03, 2025 (GLOBE NEWSWIRE) -- LONGEVERON INC. (NASDAQ: LGVN), A CLINICAL STAGE REGENERATIVE MEDICINE BIOTECHNOLOGY COMPANY DEVELOPING CELLULAR THERAPIES FOR LIFE-THREATENING, RARE PEDIATRIC AND CHRONIC AGING-RELATED CONDITIONS, TODAY ANNOUNCED KEY LEADERSHIP UPDATES.

LONGEVERON ANNOUNCES KEY LEADERSHIP UPDATES

MIAMI, AUG. 20, 2025 (GLOBE NEWSWIRE) -- LONGEVERON INC. (NASDAQ: LGVN), A CLINICAL STAGE REGENERATIVE MEDICINE BIOTECHNOLOGY COMPANY DEVELOPING CELLULAR THERAPIES FOR LIFE-THREATENING, RARE PEDIATRIC AND CHRONIC AGING-RELATED CONDITIONS, TODAY ANNOUNCED THAT IT WILL PARTICIPATE IN THE H.C. WAINWRIGHT 27TH ANNUAL GLOBAL INVESTMENT CONFERENCE TAKING PLACE SEPTEMBER 8-10, 2025 IN NEW YORK CITY.

Longeveron Inc.

LGVN

Price

Financial Reports

No items found.

Press Releases

Longeveron Inc.

LGVN.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

LGVN